Key takeaway: India Glycols Limited (INDIAGLYCO) submitted a revised investor presentation on 2nd September 2026, following a typographical error in the earlier submission. The document outlines the company's four-decade history in sustainable chemistry, focusing on bio-based and renewable feedstock products. Key segments include Bio-Glycols, Bio-Glycol Ethers, Performance Chemicals, and Industrial Gases. Financial highlights show revenue growth of ~13% CAGR from FY24–FY26, driven by spirits and biofuels businesses, with EBITDA growing at ~28% CAGR. The company has demerged into three focused entities: India Glycols Limited (retaining bio-based specialty materials and chemicals), IGL Spirits Limited (spirits and biofuels), and Ennature Biopharma Limited (nutraceuticals and biopolymers). The demerger became effective on 1st September 2026. The presentation emphasizes strategic partnerships, global collaborations, and expansion into high-value markets. The company aims to achieve ₹2,000 Cr net revenue and ₹400 Cr EBITDA in the next 4–5 years through its three-block growth strategy: Sustainable Speciality Materials, Sustainable & Performance Chemicals, and Novel Technologies. The document also details operational strengths, including a 300-acre manufacturing complex in Kashipur with rail connectivity to key ports, and a joint venture with Clariant for renewable performance chemicals. The presentation includes forward-looking statements with associated risks and disclaimers.

Key takeaway: India Glycols Limited (INDIAGLYCO) presented an investor presentation on 2nd September 2026, outlining its financial performance, operational structure, and strategic initiatives. The company reported revenue growth of ~13% CAGR over FY24–FY26, driven by the expansion of its spirits and biofuels businesses, while discontinuing less profitable ventures. EBITDA grew at ~28% CAGR, reflecting strong operating leverage. The presentation detailed the demerger effective 1st September 2026, creating three independently listed entities: India Glycols Limited (retaining bio-based specialty materials, sustainable chemicals, and gases), IGL Spirits Limited (spirits and biofuels), and Ennature Bio Pharma Ltd (nutraceuticals, APIs, and biopolymers). The company highlighted its renewable feedstock focus, with 97% of raw materials being renewable, and emphasized its leadership in bio-based glycols, glycol ethers, and green solvents. Financial highlights included FY26 net revenue of INR 2,801 Cr, EBITDA of INR 492 Cr, and a 17.6% margin. The presentation also outlined strategic priorities, including scaling application-led specialty chemistries, expanding into high-value global markets, and advancing novel technologies like CCUS and catalysis. The company noted its competitive logistics advantage through a direct rail line to ICD Kashipur, enhancing export efficiency. The document also detailed the Clariant JV, contributing INR 419 Cr in sales and INR 95 Cr in PAT for FY26.

Key takeaway: The investor presentation for India Glycols Limited (IGL) outlines its strategic positioning as an integrated alcohol platform spanning consumer brands, premium spirits, and renewable bio-fuels. The company highlights its FY26 sales of ~30 million cases, with a revenue CAGR of 39% and EBITDA CAGR of 48% over FY24–26. Key operational developments include expanded manufacturing capacity, new product launches like Amazing Vodka and Zumba Lemoni, and strategic partnerships with Bacardi and Amrut Distilleries. The presentation emphasizes leadership in non-IMFL markets, particularly in Uttar Pradesh and Uttarakhand, and a strong presence in CSD and paramilitary channels. Financial highlights show net revenue growth from INR 947 crore in FY24 to INR 1,331 crore in FY26, with EBITDA rising to INR 1,470 crore in FY26. Management projects potential to nearly double EBITDA to INR 1,000 crore by FY31E, leveraging existing capacity and strategic partnerships. The presentation also details the ethanol program's growth, supported by policy initiatives and rising demand for bio-fuels.

Key takeaway: India Glycols Limited (INDIAGLYCO) reported strong financial performance in Q1 FY27, with net revenue of INR1,130 crores, up 9% year-on-year, and EBITDA of INR170 crores, up 13%. The Spirits business saw revenue growth of 5.3% to INR361 crores, with EBITDA up 14.2%, while the chemicals segment grew by 20.6% to INR362 crores. Bio-Fuel revenue reached INR323 crores with an 19% EBIT increase, and Ennature Bio Pharma achieved record revenue growth of 65% and EBITDA growth of 188%. The company noted reduced finance costs and improved debt-to-equity ratios. Management highlighted strategic restructuring, including NCLT approval for demerger, which will separate Spirits, Bio-Fuel, and Bio Pharma into distinct entities. The Spirits segment emphasized premiumization and new product launches, while the chemicals business focused on innovation and sustainability. Ennature Bio Pharma's growth was driven by new customer acquisitions and product launches. Management provided guidance for FY27, including EBITDA targets exceeding INR500 crores for Spirits and aspirations for the chemicals business to reach INR2,500 crores in revenue and INR400 crores in EBITDA within four to five years. The company also discussed challenges from global events, including supply chain disruptions and fluctuating raw material prices, but noted resilience in core businesses.

Key takeaway: India Glycols Limited (IGL) reported a strong performance for Q1 FY27, with gross revenue increasing by 19% and net revenue by 9% year-over-year. EBITDA rose by 13%, while profit after tax (PAT) surged by 32%. The spirits segment generated ₹361 crore in revenue, reflecting a 5.3% increase, and EBITDA grew by 14.2%. The chemicals segment saw a 20.6% revenue increase to ₹362 crore, driven by bio-glycols and green solvents. The bio-fuel segment reported revenue of ₹323 crore, with EBIT rising 19%. The company also highlighted a successful restructuring plan approved by the NCLT, aimed at creating focused business entities. Management set a goal of achieving over ₹500 crore in EBITDA for FY27 and aspirations for ₹1,000 crore in the next 4-5 years. The presentation emphasized the company's diversified portfolio and strategic partnerships as key strengths.

Key takeaway: India Glycols Limited reported its Q4 and full year FY26 earnings during the conference call held on May 18, 2026. Management highlighted gross revenues of INR 9,827 crores, an increase of 8.7%, and net revenues of INR 4,211 crores, up 11.8%. EBITDA rose to INR 654 crores, reflecting a 24.5% increase, with an EBITDA margin of 15.5%. The company noted strong performance in Potable Spirits and Bio-Fuels, with EBITDA margins improving across segments. PAT reached INR 293 crores, up 26.8%. Management discussed challenges in the Chemicals segment, including a 10.4% decline in net revenue but an increase in EBIT margins. The call also addressed the impact of geopolitical factors on crude prices and the company's strategic focus on premiumization in the liquor segment. Overall, management expressed optimism about future growth and profitability across various business segments.

Key takeaway: India Glycols Limited (IGL) reported strong financial performance for FY26, with net revenue increasing by 11.8%, EBITDA rising by 24.5%, and PAT growing by 26.8%. In Q4FY26, net revenue was up 13.1%, EBITDA increased by 13.3%, and PAT surged by 35.7%. The Potable Spirits segment achieved ₹1,331 Cr in revenue, a 14.4% year-over-year increase, while the Bio-Fuel segment saw a 40.9% revenue growth. The company noted a decline in finance costs due to debt reduction and highlighted a significant cash generation from operations, which surged by 112.4% year-over-year. Management mentioned that the geopolitical situation has improved competitiveness for certain products but has also softened demand in some markets. Additionally, a proposed restructuring plan to demerge its businesses into separate entities is underway, aimed at enhancing focus and resource allocation for growth.

Key takeaway: India Glycols Limited (IGL) reported record revenue and EBITDA for Q3 and 9MFY26 during its earnings conference call held on February 12, 2026. Management highlighted an 11.4% increase in revenue and a 28.9% rise in EBITDA for the nine-month period, with EBITDA margins reaching 15.0%. The Potable Spirits segment showed strong performance, achieving a 17% year-on-year growth in net revenue. Management noted the challenges posed by a volatile global environment but emphasized that Asia remains a growth engine. The company has focused on premiumization and innovation in its product offerings, particularly in the Potable Spirits and Chemicals segments. Additionally, IGL reported a significant reduction in debt, which has positively impacted interest payments. The management expressed confidence in sustaining positive financial performance moving forward, supported by a diversified product portfolio and strategic partnerships.

Key takeaway: India Glycols Limited (IGL) reported record financial performance for Q3 and 9M FY26, achieving the highest net turnover and EBITDA in any quarter. The presentation highlighted a 11.4% increase in 9M revenue and a 28.9% rise in EBITDA, with EBITDA margins at 15.0%. The Potable Spirits segment saw a 17% YoY growth in net revenue, totaling ₹1,025 Cr, while the Chemicals segment delivered a 68% EBITDA increase in Q3. IGL reduced total debt by ₹582 Cr, with significant contributions from a preferential allotment. The company is implementing a dual growth strategy focusing on product innovation and regional expansion. The presentation also discussed a proposed restructuring involving the demerger of its Bio Pharma and Spirits & Biofuel businesses into separate entities, aimed at enhancing management focus and unlocking stakeholder value. Overall, IGL is positioned for sustained financial performance supported by a diversified product portfolio.